<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993872</url>
  </required_header>
  <id_info>
    <org_study_id>IMEA 064</org_study_id>
    <nct_id>NCT04993872</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Calcineurin &amp; mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF</brief_title>
  <acronym>KINETIK</acronym>
  <official_title>Pharmacokinetics of Calcineurin &amp; mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF: a Pilot Study - KINETIK (KIdNEy Transplant bIKtarvy) IMEA 064</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LAMBERT ASSOUMOU/ UNITE 1136 INSERM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sebastien GALLIEN/Henri Mondor University Hospital- Infectiology Department</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>THOMAS STEHL/ HENRI MONDOR HOSPITAL-Department of Nephrology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) is a critical comorbidity for patients living with HIV (PLWH),&#xD;
      with an estimated prevalence between 2.4 and 17%, leading to end-stage renal disease 3 to 6&#xD;
      fold more than non-HIV population. However kidney transplantation for PLWH has become the&#xD;
      first-line therapy for end-stage renal disease, with an enhanced survival benefit compared to&#xD;
      remaining on dialysis.&#xD;
&#xD;
      Management of antiretroviral therapy (ART) in HIV-infected kidney transplant recipients&#xD;
      (HIV-KTR) has historically been problematic because of the potential nephrotoxicity of some&#xD;
      antiretroviral drugs and the interactions between calcineurin inhibitors, mTOR inhibitors,&#xD;
      and ritonavir or cobicistat-boosted containing-ART. The use of tenofovir disoproxil fumarate&#xD;
      (TDF), a widely recommended nucleotide analogue for the treatment of both HIV and&#xD;
      HIV/hepatitis B virus (HBV) co-infection, is restricted in vulnerable kidney population as&#xD;
      HIV-KTR due to its major potential toxicity consistent with tubular dysfunction and rarely&#xD;
      with a progressive sustained decline in renal function. The optimal long-term ART regimen is&#xD;
      not known in HIV-KTR, though it makes intuitive sense to avoid regimens containing TDF, given&#xD;
      its potential nephrotoxicity. Nevertheless the potent virological efficacy of TDF both on HIV&#xD;
      and HBV and its highest in-vitro barrier to resistance among the Nucleoside Reverse&#xD;
      Transcriptase Inhibitors makes tenofovir use highly recommended or even essential in HIV/HBV&#xD;
      co-infections.&#xD;
&#xD;
      Tenofovir alafenamide (TAF) and bictegravir (BIC) are 2 novel antiretroviral drug available&#xD;
      in HIV treatment in combination with emtricitabine (F) (B/F/TAF):&#xD;
&#xD;
      * TAF is a novel prodrug of tenofovir that may offer improved renal safety over TDF. TAF is&#xD;
      more stable in plasma and is metabolized intracellularly by cathepsin A, an enzyme that is&#xD;
      highly expressed in lymphoid tissues. Therefore, TAF can achieve higher intracellular levels&#xD;
      of the active moiety tenofovir diphosphate, with lower levels of circulating tenofovir when&#xD;
      compared with TDF. This more targeted treatment could potentially result in fewer renal and&#xD;
      bone complications despite the same clinical efficacy as TDF. TAF was approved for use in&#xD;
      PLWH with mild-moderate CKD (eGFR: 30-69 mL/min).&#xD;
&#xD;
      The availability of TAF seems a potential addition to the antiretroviral armamentarium in&#xD;
      HIV-KTR. * BIC is a novel second-generation integrase strand transfer inhibitor (INSTI) has a&#xD;
      high in-vitro barrier to resistance and in-vitro activity against most INSTI-resistant&#xD;
      variants and has low potential for clinically meaningful drug-drug interactions. BIC has been&#xD;
      recently approved by the FDA, in coformulated B/F/TAF for the treatment of HIV-1 infection in&#xD;
      antiretroviral naïve subjects and in those with suppressed viremia.&#xD;
&#xD;
      No data are available yet with TAF use in HIV-infected kidney transplant recipients as well&#xD;
      as with BIC, especially about potential drug-to-drug interactions with immunosuppressive&#xD;
      drugs such as calcineurin &amp; mTOR inhibitors.&#xD;
&#xD;
      At last simplification to a single tablet regimen (STR) may offer a once-daily option for&#xD;
      HIV-KTR who have multiple comorbidities, often requires complex regimens with a high pill&#xD;
      burden.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 18, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in calcineurin &amp; mTOR inhibitors' blood concentrations from baseline (BL) to W2 after switch to B/F/TAF</measure>
    <time_frame>Week 2</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV-infected Patient Kidney Transplant Recipient</condition>
  <arm_group>
    <arm_group_label>BIC/FTC/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Development phase 4: Biktarvy®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biktarvy Tab</intervention_name>
    <description>Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.</description>
    <arm_group_label>BIC/FTC/TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • HIV-1 infected patients &gt; 18 years&#xD;
&#xD;
               -  Antiretroviral treatment switch to BIC/FTC/TAF decided in standard care by&#xD;
                  physician&#xD;
&#xD;
               -  Kidney transplant recipient ≥ 3 months&#xD;
&#xD;
               -  Receiving calcineurin and/or mTOR inhibitors without change in doses ≥ 4 weeks&#xD;
&#xD;
               -  Plasma HIV RNA ≤ 50 cpml ≥ 6 months (1 blip permitted 200cp/ml)&#xD;
&#xD;
               -  eGFR (CKD-EPI) ≥ 30 ml/mn/1.73m2&#xD;
&#xD;
               -  Written consent&#xD;
&#xD;
               -  GSS to BIC/FTC/TAF ≥ 2&#xD;
&#xD;
               -  Active contraception in potential child-bearing women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or intolerance to one of the following drug or to any of excipients: FTC, TDF,&#xD;
             INSTI&#xD;
&#xD;
          -  Current ART containing TAF&#xD;
&#xD;
          -  HIV-2 or HIV-1/HIV-2 co-infection&#xD;
&#xD;
          -  Patients with severe hepatic impairment (Child-Pugh Class C)&#xD;
&#xD;
          -  Patient without health coverage&#xD;
&#xD;
          -  Pregnancy and breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV+,,KIDNEY TRANSPLANT, BIKTARVY,cALCINEURIN? mTOR</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

